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Abstract
The role of interferon-c release assays in the diagnosis of active tuberculosis disease is uncertain, and recent guidelines do not support their
routine use. We reviewed the clinical records of 415 patients who had a QuantiFERON-TB Gold In-Tube assay between 29 June 2005 and
28 October 2010 to determine its performance in the diagnosis of active tuberculosis disease in a low prevalence setting, speciﬁcally in
human immunodeﬁciency virus (HIV) -positive and HIV-negative patients, those of UK and non-UK origin, and those with pulmonary and
extrapulmonary disease. For the diagnosis of active tuberculosis disease the overall sensitivity of QuantiFERON-TB Gold In-Tube assay was
71.4% (95% CI 59.3–81.1), speciﬁcity was 81.0% (95% CI 75.5–85.6) and negative predictive value was 92.6% (95% CI 88.2–95.5). No
signiﬁcant difference in sensitivity was seen in culture-positive and culture-negative tuberculosis, in pulmonary and extrapulmonary disease,
or with HIV infection. Speciﬁcity and negative predictive value were signiﬁcantly higher in patients of UK origin compared with those of
non-UK origin (89.3% (95% CI 83.3–93.3) and 97.1% (95% CI 92.7–98.9) versus 66.3% (95% CI 55.6–75.5) and 83.3% (95% CI 72.6–90.4)).
Our study suggests that there may be a role for interferon-c release assays in excluding active tuberculosis disease, particularly
extrapulmonary disease, in patients originating from areas of low tuberculosis incidence, with a negative test highly predictive of a lack of
active tuberculosis disease in this group. We cannot support the use of these assays in the diagnosis of active tuberculosis infection in
patients from areas of higher incidence.
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Background
Interferon-c release assays (IGRA) are increasingly used in the
diagnosis of latent tuberculosis (TB) infection [1,2]. Their role
in the diagnosis of active TB disease is less clear, with recent
UK guidelines not supporting their use as a routine diagnostic
tool [3,4]. Nevertheless, despite apparent uncertainty in the
interpretation of their results, their use continues in the
diagnosis of active TB disease in clinical practice.
Recent meta-analyses of IGRA in the diagnosis of active
TB disease in a variety of geographical and clinical settings
report sensitivity of 80–85% and speciﬁcity of 79–84% [5,6].
Higher sensitivity is reported in human immunodeﬁciency
virus (HIV) -negative versus HIV-positive patients [7].
Negative predictive values (NPV) has been reported from
67.6 to 87% [8,9].
Newcastle upon Tyne is in north-east England, a region with a
low reported TB incidence of 5.4 cases per 100 000 population in
2010 (http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/
HPAweb_C/1287147464622). We undertook the following
study to assess the use of the QuantiFERON-TB Gold In-
Tube assay (QFT-GIT, Cellestis, Chadstone, VA, Australia)
within our department, and to determine its sensitivity,
speciﬁcity and NPV in the diagnosis of active TB disease in a
low prevalence setting, speciﬁcally comparing HIV-positive
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and HIV-negative patients, those of UK and non-UK origin,
and those with pulmonary (PTB) and extrapulmonary (EPTB)
disease.
Methods
Clinical records of patients who had QFT-GIT requested
through our unit between 29 June 2005 and 28 October 2010
were reviewed. Data collected included the indication for
QFT-GIT assay, ﬁnal diagnosis, site of TB infection, TB culture
and histology reports, sex, age, nationality, HIV status, and
CD4 count if HIV positive.
Cases were assigned into ﬁve predeﬁned diagnostic cate-
gories, similar to those used in previous studies [9]:
1. Culture-conﬁrmed TB disease with supporting clinical and
radiological ﬁndings;
2. Culture-negative highly probable cases with clinical and
radiological features highly suggestive of TB disease, a
decision made to treat by a clinician with an appropriate
response to therapy, and supportive histology if available,
including cases where culture was not done;
3. Clinically indeterminate cases where not possible to conﬁrm
or exclude a diagnosis of TB disease;
4. Symptomatic patients where active TB disease excluded, all
microbiological samples smear and culture negative for TB,
and an alternative diagnosis identiﬁed;
5. Asymptomatic latent infection with QFT-GIT requested for
screening purposes only.
Duplicate tests, patients on whom insufﬁcient clinical data
were available, clinically indeterminate (category 3), and
asymptomatic cases (category 5) were excluded. Analysis
was undertaken comparing patients with active TB disease
(categories 1 and 2) with symptomatic patients with an
alternative diagnosis (category 4) acting as controls. Sensitivity,
speciﬁcity and NPV were calculated for QFT-GIT overall, in
HIV-positive versus HIV-negative patients, those of UK versus
non-UK origin, and those with PTB versus EPTB. The 95% CI
were calculated using the Wilson score method. Indetermi-
nate results were treated as false-negative when calculating
sensitivity and false-positive when calculating speciﬁcity and
NPV.
QFT-GIT and TB culture were performed at the Newcas-
tle-upon-Tyne Health Protection Agency Regional Centre for
Mycobacteriology; QFT-GIT in accordance with manufac-
turer’s guidelines [10], and TB culture using an automated
liquid mycobacterial culture system (BacT/ALERT 3D,
bioMerieux, Marcy l’Etoile, France) supported by L€owen-
stein–Jensen solid medium.
Acid-fast microscopy was performed on all samples sub-
mitted for mycobacterial culture with PCR performed selec-
tively according to national guidelines [1]. As microscopy is not
speciﬁc for Mycobacterium tuberculosis and the number of
samples on which PCR was performed is low, comparative
data against these parameters would not be statistically valid.
Hence, IGRA results are compared with mycobacterial
culture, the reference standard for the laboratory diagnosis
of TB, and to clinically diagnosed highly probable cases of TB
disease. Tuberculin skin tests were not routinely performed
and therefore not included in the analysis.
Results
From 415 QFT-GIT requested, 120 were excluded from
further analysis (28 insufﬁcient data, 19 duplicate tests, 20
clinically indeterminate cases, 53 asymptomatic screening
cases). From the remaining 295 symptomatic patients 42 had
culture-positive TB, 21 had culture-negative TB and 232 had an
alternative diagnosis.
Overall, 53% were male patients; median age was 40 years;
55% were of UK origin, 20% were from Africa, 19% were from
the Indian subcontinent, 3% were from the Middle East, and 2%
and 1% were from other Asian and other European countries,
respectively; 17% were HIV-positive with a median CD4 count
of 329 cells/lL (range 28–1060) (Table 1). Forty-six (73%) of
those with TB had EPTB, 9 (14%) had PTB, 7 (11%) had mixed
PTB and EPTB and 1 (2%) had miliary TB.
For the diagnosis of active TB disease the overall sensitivity
of QFT-GIT was 71.4% (95% CI 59.3–81.1), speciﬁcity was
81.0% (95% CI 75.5–85.6) and NPV was 92.6% (95% CI 88.2–
95.5). No signiﬁcant difference in sensitivity was seen in
culture-positive TB (76.2% (95% CI 61.5–86.5)) compared with
culture-negative TB (61.9% (95% CI 40.9–79.3)) or in PTB
(75.0% (95% CI 50.5–89.8)) compared with EPTB (71.7% (95%
CI 58.4–82.0)). Speciﬁcity and NPV were signiﬁcantly higher in
TABLE 1. Demographic and clinical characteristics
All Active TB
Alternative
diagnosis
n (%) 295 63 (21) 232 (79)
Male sex (%) 156 (53) 39 (62) 117 (50)
Age, median years (range) 40 (16–90) 33 (17–90) 42 (16–82)
Origin (%)
UK 163 (55) 14 (22) 149 (64)
Africa 59 (20) 19 (30) 40 (17)
Indian subcontinent 55 (19) 23 (37) 32 (14)
Middle East 8 (3) 4 (6) 4 (2)
Other Asia 7 (2) 3 (5) 4 (2)
Other European 3 (1) – 3 (1)
HIV +ve (%)
Median CD4 (range)
51 (17)
329 (28–1060)
14 (22)
261 (93–891)
37 (16)
350 (28–1060)
HIV, human immunodeﬁciency virus; TB, tuberculosis.
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patients of UK origin compared with those of non-UK origin
(89.3% (95% CI 83.3–93.3) and 97.1% (95% CI 92.7–98.9)
versus 66.3% (95% CI 55.6–75.5) and 83.3% (95% CI 72.6–
90.4)) (Table 2).
In all HIV-infected patients the sensitivity of QFT-GIT was
71.4% (95% CI 45.4–88.3), speciﬁcity was 81.1% (95% CI 65.8–
90.5) and NPV was 90.9% (95% CI 76.4–96.9) for the diagnosis
of active TB disease. There was no signiﬁcant difference in the
performance of the assay in patients with CD4 counts of
<200 cells/lL (Table 3).
Discussion
This study conﬁrms the relatively low overall sensitivity and
speciﬁcity of QFT-GIT for the diagnosis of active TB disease
seen in previous studies [5,6] and reinforces recommendations
that IGRA should not be used routinely in the diagnosis of
active TB disease [2–4]. There was no signiﬁcant difference in
the performance of the assay when comparing culture-positive
and culture-negative and pulmonary and extrapulmonary
disease, nor when comparing HIV-positive and HIV-negative
individuals.
Of note, speciﬁcity and NPV were signiﬁcantly higher in
patients of UK origin compared with those of non-UK origin
(89.3% and 97.1% versus 66.3% and 83.3%). Although a greater
proportion of patients of UK origin had PTB compared with
those of non-UK origin (55 versus 16%), overall TB culture
positivity was greater in patients of non-UK origin (75 versus
64%). IGRA has been shown to have improved speciﬁcity in
patients with EPTB compared with PTB with similar sensitivity
in each group [11]. It therefore seems likely that the difference
in speciﬁcity in the two groups in our study reﬂects a higher
prevalence of latent TB infection in patients of non-UK origin
rather than differences in disease site. The high NPV in
UK-born patients reﬂects not only the low incidence in this
TABLE 2. Overall analysis
Patient group QFT-GIT result TB Non-TB Sensitivity Speciﬁcity (95% CI) NPV (95% CI)
All patients 63 232b 71.4% (59.3–81.1) 81.0% (75.5–85.6) 92.6% (88.2–95.5)
Positive 45 30
Negative 15 188
Indeterminate 3 14
Culture positive 42 – 76.2% (61.5–86.5) – –
Positive 32
Negative 8
Indeterminate 2
Culture negative 21 – 61.9% (40.9–79.3) – –
Positive 13
Negative 7
Indeterminate 1
PTB 16a – 75.0% (50.5–89.8) – –
Positive 12
Negative 2
Indeterminate 2
EPTB 53a – 71.7% (58.4–82.0) – –
Positive 38
Negative 13
Indeterminate 2
UK-born 14 149 57.1% (32.6–78.6) 89.3% (83.3–93.3) 97.1% (92.7–98.9)
Positive 8 6
Negative 4 133
Indeterminate 2 10
Non-UK born 49 83 75.5% (61.9–85.4) 66.3% (55.6–75.5) 83.3% (72.6–90.4)
Positive 37 24
Negative 11 55
Indeterminate 1 4
EPTB, extrapulmonary tuberculosis; NPV, negative predictive value; PTB, pulmonary tuberculosis; QFT-GIT, QuantiFERON-TB Gold In-Tube assay.
aIncludes seven with PTB and EPTB.
bIncludes eight atypical mycobacterial infections.
TABLE 3. HIV-positive patients
Patient population QFT-GIT result TB Non-TB Sensitivity (95% CI) Speciﬁcity (95% CI) NPV (95% CI)
All HIV 14 37 71.4% (45.4–88.3) 81.1% (65.8–90.5) 90.9% (76.4–96.9)
Positive 10 5
Negative 3 30
Indeterminate 1 2
CD4 < 200 6 10 83.3% (43.7–97.0) 70.0% (39.7–89.2) 87.5% (52.9–97.8)
Positive 5 2
Negative 1 7
Indeterminate 0 1
HIV, human immunodeﬁciency virus; NPV, negative predictive value; QFT-GIT, QuantiFERON-TB Gold In-Tube assay; TB, tuberculosis.
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group, but also a signiﬁcant number of IGRA requested in
patients with non-speciﬁc symptoms unlikely to have TB
infection.
Previous studies of IGRA in areas of low TB incidence have
focused largely on the diagnosis of latent TB infection and there
are few studies looking at the diagnosis of active disease in this
setting. Winqvist et al. [8] compared the performance of
QuantiFERON-TB Gold in immigrants from countries of high
and medium TB incidence with native Swedes and found the
performance to be similar; 62.9% in this cohort had PTB and
IGRA performancewas noted again to be better in EPTB. Detjen
et al. [12] reported excellent performance of QFT-GIT in the
diagnosis of active TB disease in children in Germany but did not
compare those of German and non-German origin. Vesenbeckh
et al. [13] demonstrated a sensitivity of QFT-GIT for the
diagnosis of active TB disease inGermany of 82%; 53/61 had PTB
and there were again no data on patient country of origin.
This is contrasted by Metcalfe et al. [14] who reported
sensitivity of QFT-GIT of 69% (95% CI 52–83) and speciﬁcity
of 52% (95% CI 41–63) for the diagnosis of active PTB disease
in low and middle income countries with high TB incidence. In
South Africa, Ling et al. [15] demonstrated a sensitivity of 76%
(95% CI 68–83) and speciﬁcity 42% (95% CI 36–49) for
QFT-GIT for the diagnosis of active TB disease, independent of
HIV status and CD4 count.
Our study suggests that there may be a role for IGRA in
excluding active TB disease in patients originating from areas of
low TB incidence, with a negative test being highly predictive of
a lack of active TB disease in this group. As a higher proportion
of these patients had PTB, when microbiological diagnosis
should be more straightforward, it seems sensible to restrict
this role to patients from areas of low TB incidence where
EPTB is suspected. This is supported by previous studies
demonstrating improved performance of IGRA in EPTB and in
areas of low TB incidence. Based on this study we cannot
support the use of IGRA in the diagnosis of active TB infection
from areas of higher incidence.
The study is limited by being retrospective, with relatively
small numbers of patients allowing only limited subgroup
analysis, and with one observer there is the potential for bias.
As a consequence of local arrangements, the respiratory
department in our centre sees a larger proportion of PTB
presenting, hence the high proportion of patients with EPTB
seen in this cohort.
In conclusion, this study demonstrates signiﬁcantly higher
speciﬁcity and NPV of QFT-GIT for the diagnosis of active TB
disease in patients from areas of low TB incidence compared
with those from areas of higher TB incidence. Although there
may be a limited role for IGRA in excluding active TB disease,
particularly EPTB, in this group, attempts at clinical, radiolog-
ical and microbiological diagnosis remain paramount, even
when a rapidly available blood test appears tempting.
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